Difference (from prior minor revision) Added: 2a3 > * [[Aberrent glycosylation in malignant and pre-malignant states]] Added: 3a5 > * [[P glycoprotein and ABO blood group]] C O N T E N T S
See Also
Many modifications in glycosylation of cell surface glycoconjugates have been described in cancer (1, 2). For the most part, the biological roles of these alterations are not well defined. Thus the expression of ABH antigens is subject to considerable variations on malignant transformation, and its significance is unclear (3). A loss of A and B antigens is observed in most types of carcinomas, such as carcinomas from the buccal epithelium, stomach, proximal colon, pancreas, larynx, lung, endometrium, ovary, prostate, urinary bladder, and breast. However, these antigens appear on carcinomas derived from some tissues where they are normally not present, such as the colorectal epithelium, liver parenchyme, and thyroid. The loss of A and B antigens is associated with a poor prognosis in carcinomas of the lung, urinary bladder, and head and neck. Inversely, in the case of colorectal carcinomas, it is their presence that is a sign of unfavorable outcome (4). In addition, a higher incidence of various types of carcinomas is observed for blood group A and B individuals compared with blood group O individuals (5, 6, 7, 8, 9,10, 11, 12,13). Transfection of the A or B enzymes’ cDNA or selection of A-positive subpopulations of human colorectal carcinoma cell lines showed that the presence of the A and B antigens was associated with a reduced motility on matrigel. These observations may explain why the loss of A and B antigens is associated with a bad prognosis in some types of carcinomas because the A and B antigens would decrease the cells metastatic potential. However, they cannot account for the increased frequency of cancers in blood group A and B individuals or for the meaning of the appearance of A and B antigens from the early stages of colorectal carcinoma development.[1] AbstractsBlood group antigens as tumor markers, parasitic/bacterial/viral receptors, and their association with immunologically important proteinsImmunol Invest. 1995 Jan-Feb;24(1-2):213-32. Garratty G. Research Department, American Red Cross Blood Services, Los Angeles, CA 90006, USA.
Tumor-associated carbohydrate antigens related to blood group carbohydratesGan To Kagaku Ryoho. 1986 Apr;13(4 Pt 2):1395-401. Hirohashi S.
Distribution of blood group antigens and CA 19-9 in gastric cancers and non-neoplastic gastric mucosa.Gann. 1984 Jun;75(6):540-7. Hirohashi S, Shimosato Y, Ino Y, Tome Y, Watanabe M, Hirota T, Itabashi M.
Expression of the blood group antigens A and B in carcinoma of the urinary bladderTichy M, Jansa P, Student V, Ticha V, Vanak J. Bratisl Lek Listy. 1992 Aug;93(8):415-20. Katedra patologicke anatomie LF Univerzity Palackeho, Olomouci.
A further case of Tn-polyagglutinationFolia Haematol Int Mag Klin Morphol Blutforsch. 1979;106(3):426-34. Lahmann N.
Isoantigenic expression of Forssman glycolipid in human gastric and colonic mucosa: Its possible identity with “A-like antigen” in human cancerProc Natl Acad Sci U S A. 1977 July; 74(7): 3023–3027. S. Hakomori, S.-M. Wang, and W. W. Young, Jr.
Tn-polyagglutinability of red blood cells and acquired A-like specificityTransfusion. 1977 May-Jun;17(3):272-6. Related Articles, Links Kourteva BT, Manolova VR, Mitova DK.
A-like specificity in Tn-activated erythrocytes of blood group BKurteva B. Folia Haematol Int Mag Klin Morphol Blutforsch. 1977;104(2):277-82.
The blood group A-like site on the carcinoembryonic antigenCancer Res. 1973 Nov;33(11):2821-4. Gold JM, Gold P. Links1. Hakomori, S.I. (1996) Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res., 56, 5309–5318 2. Kim, Y.J. and Varki, A. (1997) Perspective on the significance of altered glycosylation in cancer. Glycoconj. J., 14, 569–576 3. Hakomori, S. (1999) Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer. Biochim. Biophys. Acta, 1473, 247–266. 4. Le Pendu, J., Marionneau, S., Cailleau-Thomas, A., Rocher, J., Le Moullac-Vaydie, B., and Clément, M. (2001) ABH and Lewis histo-blood group antigens in cancer. APMIS, 109, 9–31 5. Annese, V., Minervini, M., Gabbrielli, A., Gambassi, G., and Manna, R. (1990) ABO blood groups and cancer of the pancreas. Int. J. Pancreatol., 6, 81–88. 6. Bjorkholm, E. (1984) Blood group distribution in women with ovarian cancer. Int. J. Epidemiol., 13, 15–17. 7. Henderson, J., Seagroat, V., and Goldacre, M. (1993) Ovarian cancer and ABO blood groups. J. Epidemiol. Comm. Health, 47, 287–289. 8. Kaur, I., Singh, I.P., and Bhasin, M.K. (1992) Blood groups in relation to carcinoma of cervix uteri. Hum. Hered., 42, 324–326 9. Mourant, A.E., Kopec, A.C., and Domaniewska-Sobczak, K. (1978) Blood groups and diseases. A study of associations of diseases with blood groups and other polymorphisms. Oxford: Oxford University Press. 10. Slater, G., Itzkowitz , S., Azar, S.S., and Aufses, A.H. (1993) Clinicopathological correlations of ABO and Rhesus blood type in colorectal cancer. Dis. Colon Rectum, 36, 5–7. 11. Su, M., Lu, S.M., Tian, D.P., Zhao, H., Li, X.Y., Li, D.R., and Zheng, Z.C. (2001) Relationship between ABO blood groups and carcinoma of the esophagus and cardia in Chaoshan inhabitants of China. World J. Gastroenterol., 7, 657–661. 12. Vioque, J. and Walker, A.M. (1991) Pancreatic cancer and ABO blood types: a study of cases and control. Med. Clin., 96, 761–764 13. You, W.C., Ma, J.L., Liu, W., Gail, M.H., Chang, Y.S., Zhang, L., Hu, Y.R., Fraumeni, J.F., and Xu, G.W. (2000) Blood type and family cancer history in relation to precancerous gastric lesions. Int. J. Epidemiol., 29, 405–407 |
COMPLETE BLOOD TYPE ENCYCLOPEDIAThe Complete Blood Type Encyclopedia is the essential desk reference for Dr. D'Adamo's work. This is the first book to draw on the thousands of medical studies proving the connection between blood type and disease. Click to learn more
Click the Play button to hear to Dr. Peter J. D'Adamo discuss .
|
The statements made on our websites have not been evaluated by the FDA (U.S. Food & Drug Administration).
Our products and services are not intended to diagnose, cure or prevent any disease. If a condition persists, please contact your physician.
Copyright © 2015-2023, Hoop-A-Joop, LLC, Inc. All Rights Reserved. Log In